What appetite‑stimulating treatments are appropriate for an 82‑year‑old woman with recent gastric ulceration, impaired gastric emptying, recurrent hiatal hernia, chronic non‑rheumatoid arthritis, hypertension, resolved acute liver failure from portal‑vein thrombosis, who is currently taking dicyclomine (Bentyl) four times daily, metoclopramide (Reglan), omeprazole, and Remeron (mirtazapine) for appetite stimulation?

Appetite Stimulation in Complex Gastroparesis with Multiple Comorbidities

Direct Recommendation

Continue mirtazapine (Remeron) as your primary appetite stimulant, as it is already prescribed and represents the most evidence-based pharmacologic option for appetite stimulation in gastroparesis patients, while simultaneously addressing the underlying impaired gastric emptying with optimized prokinetic therapy. 1, 2

---

Current Medication Assessment

Your patient is already receiving mirtazapine (Remeron), which is the optimal choice for appetite stimulation in this clinical context. 3, 2

Why Mirtazapine is Appropriate Here:

• Dual benefit: Mirtazapine increases appetite through antagonism of histamine H1 and serotonin 5-HT2C receptors, while also providing antiemetic effects that directly address her nausea. 3, 2
• Evidence in gastroparesis: A case report demonstrated complete remission of gastroparesis symptoms (postprandial discomfort, nausea, vomiting) within 1 week of starting mirtazapine in a patient who had failed conventional prokinetics including erythromycin, metoclopramide, domperidone, and botulinum toxin—similar to your patient's refractory presentation. 2
• Expected weight gain: In controlled trials, 7.5% of mirtazapine-treated patients gained ≥7% body weight compared to 0% on placebo, and appetite increase occurred in 17% versus 2% on placebo. 3

Critical Dosing Consideration:

• Ensure mirtazapine is dosed at 15-45 mg at bedtime to maximize appetite stimulation while leveraging its sedating properties (which occur at lower doses due to antihistamine effects). 3
• Do not abruptly discontinue if considering changes, as withdrawal symptoms including nausea and vomiting can occur. 3

---

Optimize the Underlying Gastroparesis Management

The key to improving appetite is addressing the impaired gastric emptying and nausea that suppress oral intake. 1

Step 1: Reassess Metoclopramide (Reglan) Dosing

• Current standard: Metoclopramide should be dosed at 10 mg three to four times daily (before meals and at bedtime) for a minimum of 4 weeks to constitute an adequate trial. 1, 4
• Verify your patient is receiving this dose; many patients are underdosed at 5 mg TID, which is subtherapeutic. 4
• Caution: Monitor for tardive dyskinesia risk, though this may be lower than previously estimated, especially with treatment duration <12 weeks. 1, 5

Step 2: Add or Optimize Antiemetic Therapy

Since nausea directly suppresses appetite, aggressive antiemetic management is essential:

• 5-HT3 antagonists (ondansetron 8 mg two to three times daily or granisetron 1 mg twice daily) are second-line options when metoclopramide alone is insufficient. 1, 6
• Dose escalation matters: Starting ondansetron at 4 mg once daily is subtherapeutic; effective dosing is 8 mg two to three times daily. 6
• Monitor for constipation, which is dose-limiting and particularly problematic in elderly patients with baseline autonomic dysfunction. 6

Step 3: Consider Domperidone if Available

• Domperidone 10 mg three times daily is a third-line prokinetic with fewer central nervous system side effects than metoclopramide (including lower tardive dyskinesia risk). 1, 5
• Major limitation: Requires FDA investigational new drug application in the United States, limiting practical availability. 1, 5
• Cardiac monitoring required: Risk of QT prolongation and ventricular tachycardia; avoid escalating beyond 10 mg TID. 5

Step 4: Short-Term Erythromycin for Acute Exacerbations

• Erythromycin 250 mg three times daily (or 900 mg/day total) can be used for short-term rescue therapy during acute symptom flares. 5, 6
• Critical limitation: Rapid tachyphylaxis develops, making it unsuitable for chronic use. 5
• Mechanism: Acts as motilin agonist, inducing phase 3 migrating motor complex activity. 5

---

Dietary Modifications to Enhance Tolerance

Implement a structured dietary approach for at least 4 weeks concurrently with pharmacotherapy: 1, 4

• Small, frequent meals (6 meals daily rather than 3) to reduce gastric distension. 1, 4
• Replace solids with liquids such as soups, smoothies, and nutritional supplements to facilitate gastric emptying. 1, 4
• Low-fat, low-fiber diet: Fat delays gastric emptying; fiber forms bezoars in delayed emptying states. 1, 4
• Small particle size: Puree or blend foods to <1-2 mm particles. 1, 4

---

What NOT to Use

Avoid GLP-1 Receptor Agonists

• These medications (semaglutide, liraglutide, etc.) further delay gastric emptying and will exacerbate her gastroparesis symptoms. 4, 7

Reassess Dicyclomine (Bentyl)

• Anticholinergics counteract prokinetic effects of metoclopramide and may worsen gastric emptying. 6
• While dicyclomine addresses abdominal cramping, consider whether the benefit outweighs the potential worsening of delayed emptying. 1, 6
• If cramping persists, consider switching to peppermint oil as an alternative antispasmodic with less impact on motility. 1

---

Special Considerations for This Patient

Age-Related Factors (82 years old):

• Increased sensitivity to sedation from mirtazapine; monitor for falls risk and daytime somnolence. 3
• Hyponatremia risk: Elderly patients are more susceptible; monitor sodium levels periodically. 3

History of Portal Vein Thrombosis:

• While resolved, this history suggests potential for impaired hepatic drug metabolism. 8
• Mirtazapine undergoes hepatic metabolism; use with caution and monitor for elevated transaminases (though mirtazapine itself can cause ALT elevations in 2% of patients). 3

Concurrent Omeprazole:

• Continue omeprazole for gastric ulcer healing; it does not negatively interact with appetite stimulation strategies. 9
• Caution: Gastroparesis impairs oral medication absorption; consider that all oral medications may have reduced bioavailability. 10

---

Algorithm for Refractory Cases

If appetite remains poor despite optimized mirtazapine and gastroparesis management:

1. Verify adequate metoclopramide dosing (10 mg QID for ≥4 weeks). 1, 4
2. Add ondansetron 8 mg TID for breakthrough nausea. 1, 6
3. Consider domperidone if accessible (requires IND application). 1, 5
4. Trial short-term erythromycin (250 mg TID for 2-4 weeks) during acute flares. 5
5. Evaluate for gastric electrical stimulation if symptoms remain refractory after 18+ months of medical management, though this addresses nausea/vomiting rather than appetite directly. 4

---

Common Pitfalls to Avoid

• Underdosing metoclopramide: 5 mg TID is insufficient; use 10 mg QID. 4
• Underdosing ondansetron: 4 mg daily is subtherapeutic; use 8 mg TID. 6
• Continuing anticholinergics: Dicyclomine may worsen gastric emptying. 6
• Abrupt mirtazapine discontinuation: Taper gradually to avoid withdrawal-induced nausea. 3
• Ignoring dietary modifications: Pharmacotherapy alone is insufficient; dietary changes are foundational. 1, 4